Lantern Pharma Inc
Research Lantern Pharma Inc (LTRN) on Bullrun: market cap USD 27.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLTRN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 27.81M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 15.91M
- Free cash flow-USD 3.77M
Valuation Snapshot
latest market cap is USD 27.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 17.12M | -USD 15.68M | n/a | -1.57 | USD 4.42M | USD 78.54K | USD 6.53M |
| FY2024 | USD 0 | -USD 20.78M | -USD 17.83M | n/a | -1.93 | USD 7.51M | USD 243.66K | USD 21.19M |
| FY2023 | n/a | -USD 15.96M | -USD 14.37M | n/a | -1.47 | USD 21.94M | USD 234.47K | USD 40.91M |
| FY2022 | n/a | -USD 14.26M | -USD 12.80M | n/a | -1.31 | USD 37.20M | USD 130.71K | USD 56.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 27.81M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 34.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 34.40M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 45.90M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 65.58M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 88.49M | n/a | n/a | n/a |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lantern Pharma Inc's market cap?
Lantern Pharma Inc's market capitalization is USD 27.81M.
What does Lantern Pharma Inc do?
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of.